Neue ESC-Leitlinien Herzinsuffizienz 2012 – Was hat sich für unsere Praxis geändert?

Abstract

The current ESC-guidelines for the diagnosis and treatment of heart failure state clear-cut recommendations for the treatment of symptomatic patients with reduced LV-function: A combination of three neuro-humoral antagonists, i. e., beta-blockers, ACE inhibitors and aldosterone antagonists, all given in high doses, is the mainstay of therapy. Driven by new data, ivabradine is now recommended if the patient is further symptomatic and has a sinus tachycardia ≥ 70 /min. Cardiac resynchronization therapy (CRT) is now recommended even in patients with milder symptoms (NYHA II) when in sinus rhythm. In contrast, no evidence-based treatment exists for heart failure with preserved LV-function. In those patients, optimal treatment of the co-morbidities (CHD, hypertension, diabetes, sleep-disordered breathing, atrial fibrillation) is essential to prevent the progression to/of heart failure. For the treatment of comorbidities a holistic approach is recommended.

• Literatur

• 1 McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2012; 14: 803-869
• 2 Zannad F, McMurray JJV, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2010; 364: 11-21
• 3 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2011; 376: 875-885
• 4 Levis RV, McMurray JJV, McDevitt DG. Effects of atenonol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13: 1-6
• 5 Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248-2261
• 6 GISSI-HF I. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2004; 372: 1231-1239
• 7 Massie BM, Collins JF, Ammon SE et al. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure. Circ 2009; 119: 1616-1624
• 8 Homma S, Thompson JLP, Pullicino PM et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med 2012; 366: 1859-1869
• 9 GISSI-HF II. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2004; 372: 1223-1230
• 10 Moss AJ, Hall WJ, Cannom DS et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med 2009; 361: 1329-1338
• 11 Tang ASL, Wells GA, Talajic M et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. N Engl J Med 2010; 363: 2385-2395
• 12 Haass M. Komorbidität bei Herzinsuffizienz: Bedeutung für die Therapie. Aktuelle Kardiologie 2012; 1: 319-325
• 13 Anker SD, Comin Colet J, Filippatos G et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361: 2436-2448